Cover Image
Read Now

CADTH Canadian Drug Expert Committee recommendation: Fluticasone Propionate (Aermony respiclick -- Teva Canada Innovation) indication : maintenance treatment of asthma in patients 12 years of age and older

The CADTH Canadian Drug Expert Committee recommends that fluticasone propionate multi-dose dry powder inhaler be reimbursed for the maintenance treatment of steroid-responsive bronchial asthma as a prophylactic therapy in patients 12 years of age and older, if the following condition is met: Flutica...

Full description

Bibliographic Details
Corporate Author: CADTH Canadian Drug Expert Committee
Format: eBook
Language:English
Published: Ottawa (ON) CADTH 2018, December 21, 2018
Edition:Final
Series:CADTH common drug review
Subjects:
Insurance, Health, Reimbursement
Fluticasone / Economics
Child
Canada
Asthma / Drug Therapy
Fluticasone / Therapeutic Use
Cost-benefit Analysis
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The CADTH Canadian Drug Expert Committee recommends that fluticasone propionate multi-dose dry powder inhaler be reimbursed for the maintenance treatment of steroid-responsive bronchial asthma as a prophylactic therapy in patients 12 years of age and older, if the following condition is met: Fluticasone propionate multi-dose dry powder inhaler should provide cost savings for drug plans relative to the lowest priced alternative inhaled corticosteroid reimbursed for the treatment of asthma
Physical Description:1 PDF file (8 pages)

Similar Items